Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2013 2
2015 1
2016 2
2017 4
2018 6
2019 4
2020 8
2021 11
2022 6
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall'Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Bladé Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P. D'Agostino M, et al. J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605179 Free article.
MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L, D'Agostino M, Gay F. Bertamini L, et al. Among authors: d agostino m. Curr Hematol Malig Rep. 2021 Apr;16(2):162-171. doi: 10.1007/s11899-021-00633-5. Epub 2021 May 5. Curr Hematol Malig Rep. 2021. PMID: 33950462 Free article. Review.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Among authors: d agostino m. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
Novel Immunotherapies for Multiple Myeloma.
D'Agostino M, Boccadoro M, Smith EL. D'Agostino M, et al. Curr Hematol Malig Rep. 2017 Aug;12(4):344-357. doi: 10.1007/s11899-017-0397-7. Curr Hematol Malig Rep. 2017. PMID: 28819882 Free PMC article. Review.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
D'Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Morè S, Corradini P, Oliva S, Ledda A, Grasso M, Pavone V, Ronconi S, Vincelli ID, Ballanti S, Velluti C, Cellini C, Gozzetti A, Palmas AD, Gamberi B, Mancuso K, Paris L, Zambello R, Petrucci MT, Bruno B, Musto P, Gay F. D'Agostino M, et al. Blood. 2024 Feb 15;143(7):592-596. doi: 10.1182/blood.2023022080. Blood. 2024. PMID: 38048557
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Bandini C, Mereu E, Paradzik T, Labrador M, Maccagno M, Cumerlato M, Oreglia F, Prever L, Manicardi V, Taiana E, Ronchetti D, D'Agostino M, Gay F, Larocca A, Besse L, Merlo GR, Hirsch E, Ciarrocchi A, Inghirami G, Neri A, Piva R. Bandini C, et al. Among authors: d agostino m. Exp Hematol Oncol. 2023 Aug 10;12(1):71. doi: 10.1186/s40164-023-00434-x. Exp Hematol Oncol. 2023. PMID: 37563685 Free PMC article.
CD38 as an immunotherapeutic target in multiple myeloma.
Bonello F, D'Agostino M, Moscvin M, Cerrato C, Boccadoro M, Gay F. Bonello F, et al. Among authors: d agostino m. Expert Opin Biol Ther. 2018 Dec;18(12):1209-1221. doi: 10.1080/14712598.2018.1544240. Epub 2018 Nov 13. Expert Opin Biol Ther. 2018. PMID: 30394809 Free article. Review.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
Zamagni E, Oliva S, Gay F, Capra A, Rota-Scalabrini D, D'Agostino M, Belotti A, Galli M, Racca M, Zambello R, Gamberi B, Albano D, Bertamini L, Versari A, Grasso M, Sgherza N, Priola C, Fioritoni F, Patriarca F, De Cicco G, Villanova T, Pascarella A, Zucchetta P, Tacchetti P, Fanti S, Mancuso K, Barbato S, Boccadoro M, Musto P, Cavo M, Nanni C. Zamagni E, et al. Among authors: d agostino m. EClinicalMedicine. 2023 Jun 9;60:102017. doi: 10.1016/j.eclinm.2023.102017. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396807 Free PMC article.
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
Oliva S, Genuardi E, Paris L, D'Agostino M, Rogers J, Rota-Scalabrini D, Jacob AP, Patriarca F, Luppi M, Bertazzoni P, Velluti C, Capra A, Saraci E, Rossi M, Allegra A, Mina R, Gentile M, Kirsch IR, Belotti A, Cavo M, Bruno B, Musto P, Boccadoro M, Zamagni E, Gay F. Oliva S, et al. Among authors: d agostino m. EClinicalMedicine. 2023 Jun 9;60:102016. doi: 10.1016/j.eclinm.2023.102016. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37396800 Free PMC article.
51 results